KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Debt to Equity (2016)

Vertex Pharmaceuticals has reported Debt to Equity over the past 6 years, most recently at $0.22 for Q4 2016.

  • Quarterly results put Debt to Equity at $0.22 for Q4 2016, down 16.94% from a year ago — trailing twelve months through Dec 2016 was $0.22 (down 16.94% YoY), and the annual figure for FY2016 was $0.22, down 16.94%.
  • Debt to Equity for Q4 2016 was $0.22 at Vertex Pharmaceuticals, down from $0.25 in the prior quarter.
  • Over the last five years, Debt to Equity for VRTX hit a ceiling of $0.3 in Q1 2015 and a floor of $0.22 in Q4 2016.
  • Median Debt to Equity over the past 3 years was $0.27 (2014), compared with a mean of $0.26.
  • Biggest five-year swings in Debt to Equity: rose 7.39% in 2015 and later fell 16.94% in 2016.
  • Vertex Pharmaceuticals' Debt to Equity stood at $0.27 in 2014, then grew by 0.36% to $0.27 in 2015, then fell by 16.94% to $0.22 in 2016.
  • The last three reported values for Debt to Equity were $0.22 (Q4 2016), $0.25 (Q3 2016), and $0.25 (Q2 2016) per Business Quant data.